



## REATA PHARMACEUTICALS, INC. ANNOUNCES FILING OF REGISTRATION STATEMENT FOR PROPOSED PUBLIC OFFERING

**IRVING, Texas, December 6, 2016**—Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata”), a clinical-stage biopharmaceutical company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed underwritten public offering of shares of its Class A common stock. This offering will be subject to the registration statement on Form S-1 becoming effective and subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Reata intends to use the net proceeds from the offering to advance the development of its lead product candidate, bardoxolone methyl, through a Phase 2/3 trial and additional Phase 2 programs, to advance the development of its additional lead product candidate omaveloxolone, and to provide funds for working capital and other general purposes, including clinical trials and preclinical studies.

Citigroup, Cowen and Company, and Piper Jaffray are acting as joint book-running managers for the offering.

A registration statement, including a prospectus, which is preliminary and subject to completion, relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering is being made only by means of a written prospectus. A copy of the final prospectus relating to these securities, when available, may be obtained for free from:

Citigroup Global Markets Inc.,  
c/o Broadridge Financial Solutions,  
1155 Long Island Avenue, Edgewood, NY, 11717,  
telephone: (800) 831-9146;

Cowen and Company, LLC,  
c/o Broadridge Financial Services,  
1155 Long Island Avenue, Edgewood, NY, 11717,  
Attn: Prospectus Department,  
telephone: (631) 274-2806, or fax: (631) 254-7140; or

Piper Jaffray & Co.,  
Attn: Prospectus Department,  
800 Nicollet Mall, J12S03, Minneapolis, MN, 55402,  
email: [prospectus@pjc.com](mailto:prospectus@pjc.com), or telephone: (800) 747-3924.



## **About Reata Pharmaceuticals, Inc.**

Reata Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in regulating cellular metabolism and inflammation. Our two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target important transcription factors, called Nrf2 and NF- $\kappa$ B, to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

## **Forward-Looking Statements**

This press release includes certain disclosures which contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, our ability to obtain and retain regulatory approval of our product candidates, estimates of our expenses and our needs for additional financing, and our ability to obtain additional financing for our product development activities and existing and future clinical trials and pre-clinical programs. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Reata’s filings with the U.S. Securities and Exchange Commission, including its Registration Statement on Form S-1, as amended from time to time, under the caption “Risk Factors.” The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

### **Contact:**

Reata Pharmaceuticals, Inc.  
(972) 865-2219  
[info@reatapharma.com](mailto:info@reatapharma.com)

### **Investor Relations:**

The Trout Group  
Lee M. Stern, CFA  
(646) 378-2922  
[IR@reatapharma.com](mailto:IR@reatapharma.com)